{"organizations": [], "uuid": "9c183a54bd6d2a76f37c5b0eb956ac5ee9d3f684", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "https://fm.cnbc.com/applications/cnbc.com/resources/img/editorial/2017/10/06/104758220-GettyImages-853597002.1910x1000.jpg", "site_section": "http://www.cnbc.com/id/19834788/device/rss/rss.xml", "section_title": "Asia Top News and Analysis", "url": "https://www.cnbc.com/2018/04/19/allergan-in-talks-to-acquire-shire-competing-against-takeda-pharmaceutical.html", "country": "US", "domain_rank": 767, "title": "Takeda in talks with Shire after $61 billion bid rejected", "performance_score": 0, "site": "cnbc.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "blogs", "published": "2018-04-19T16:52:00.000+03:00", "replies_count": 0, "uuid": "9c183a54bd6d2a76f37c5b0eb956ac5ee9d3f684"}, "author": "", "url": "https://www.cnbc.com/2018/04/19/allergan-in-talks-to-acquire-shire-competing-against-takeda-pharmaceutical.html", "ord_in_thread": 0, "title": "Takeda in talks with Shire after $61 billion bid rejected", "locations": [], "entities": {"persons": [{"name": "jean-pierre clatot", "sentiment": "negative"}, {"name": "takeda", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "shire", "sentiment": "negative"}, {"name": "allergan", "sentiment": "negative"}, {"name": "allergan brenton saunders", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Botox maker Allergan is in the \"early stages\" of talks to acquire drugmaker Shire , the company confirmed Thursday following media reports.\nThe discussions put Allergan in direct competition with Japan's Takeda Pharmaceutical for the London -listed drugmaker.\nShire rebuffed Takeda on Thursday, turning down an offer worth around $61 billion. Shire said the offer of $66.15 per share in cash and stock \"significantly undervalued the company, its growth prospects and pipeline.\"\nAllergan said in a statement that it has not submitted an offer and that there is no certainty of a bid. The company is required by law to announce its intention to make an offer for Shire by May 17.\nWith additional reporting from Reuters.", "external_links": [], "published": "2018-04-19T16:52:00.000+03:00", "crawled": "2018-04-19T16:58:22.020+03:00", "highlightTitle": ""}